Basic Information
| LncRNA/CircRNA Name | DLEU2 |
| Synonyms | DLEU1, BCMS, BCMS1, DLB1, DLEU2, LEU1, LEU2, LINC00021, NCRNA00021, XTP5 |
| Region | GRCh38_13:49982552-50125720 |
| Ensemble | ENSG00000231607 |
| Refseq | NR_002612 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RIP |
| Sample | liver cell line and HCC cell lines, HCC tissues and adjacent normal tissues |
| Expression Pattern | up-regulated |
| Function Description | DLEU2 was upregulated in HCC tissues, especially in those larger than 5 cm in tumor size, accompanied with vascular invasion and in worse tumor stage. Knockdown of DLEU2 attenuated proliferative, migratory and invasive abilities of SMMC7721 and HCLM3 cells. RIP assay proved that DLEU2 could interact with EZH2. Knockdown of EZH2 attenuated the inhibited proliferation in HCC cells with DLEU2 knockdown. DLEU2 accelerates the proliferative, migratory and invasive abilities of HCC cells via binding to EZH2, thus aggravating the progression of HCC. |
| Pubmed ID | 31376657 |
| Year | 2019 |
| Title | LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2 |
External Links
| Links for DLEU2 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |